| Drug Type Hematopoietic stem cell therapy | 
| Synonyms Platelets produced in vitro from proplatelets derived from peripheral blood, XJ-PLT 001, XJ-PLT001 | 
| Target- | 
| Action- | 
| Mechanism- | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Congenital Amegakaryocytic Thrombocytopenia | Preclinical | United States  | 28 Jul 2025 | |
| Bernard-Soulier Syndrome | Preclinical | United States  | 25 Apr 2025 | 





